AZD5069
As of the edition of 20 October 2026, AZD5069 is a drug known only by a code name: stopped in 2022; acts on CXCR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Code name only
- Registered trials
- 13, 1 stopped early
- Disease areas
- Lungs and airways; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CXCR2 | C-X-C chemokine receptor type 2 | P25025 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 8 | 0 | 0 |
| Phase 2 | 5 | 4 | 0 | 1 |
| All trials | 13 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Lead sponsor of trials | 2009 to now |